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doi:10.1Objective: Sinus node dysfunction is commonly associated with atrial fibrillation. There is little information
about the long-term results of pulmonary vein isolation in relation to sinus node function. The present study
was conducted to investigate whether sinus node dysfunction affects the late outcome of pulmonary vein isola-
tion in patients with persistent/permanent atrial fibrillation.
Methods: Among 76 consecutive patients with persistent/permanent atrial fibrillation who had undergone cut-
and-sew pulmonary vein isolation, 66 patients without evidence of intra-atrial thrombus by transesophageal
echography, andwhowere able to tolerate cardioversion, were enrolled. Sinus node recovery time after cardiover-
sion was examined intraoperatively. All of the patients underwent valvular surgery concomitantly (mitral in 62).
Results: Sinus node dysfunction was detected in 18 patients. These patients had a significantly lower f wave volt-
age inV1 of the electrocardiogram and a larger cardiothoracic ratio than patientswith normal sinus node function.
Hospitalmortalitywas 3%, and 3 late deaths were observed. Follow-upwas conducted for up to 72months (mean
30months), with a 100% complete follow-up rate. Therewere no significant differences in actuarial survival and
freedom from cardiac events between patients with normal and abnormal sinus node function. No thromboem-
bolic events occurred. A significantly higher proportion of patients with normal sinus node function (82%) were
free of atrial fibrillation at 4 years than patients with sinus node dysfunction (25%; P<.0001).
Conclusions: The atrial fibrillation cure rate after pulmonary vein isolation may be influenced by sinus node
function in both the early and late stages. Although further examinations are required, pulmonary vein isolation
may be an adequate treatment for persistent/permanent atrial fibrillation in patients with normal sinus node func-
tion. (J Thorac Cardiovasc Surg 2011;141:1455-60)A
C
DAlthough the Cox maze III procedure has been widely rec-
ognized as the most effective surgical treatment for patients
with persistent/permanent atrial fibrillation (AF), pulmo-
nary vein isolation (PVI) has recently been increasingly
adopted along with the introduction of energy-based tech-
niques.1-4 From a surgical viewpoint, PVI is preferable
because it requires a smaller lesion set, thus reducing the
time required for aortic crossclamping and extracorporeal
circulation. However, it is still unknown whether PVI is
sufficient for the treatment of persistent/permanent AF.
The mechanisms of persistent/permanent AF have been
not fully clarified, and the usage of various energy sources
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The Journal of Thoracic and Carthe maze procedure.5,6 In addition, there are few reports
about the late results of classic cut-and-sew PVI.
In the early Cox maze I/II era, a high incidence of pace-
maker implantation after the procedure was reported.7,8 The
surgical technique was therefore modified to avoid
incisional damage to the sinus node (SN) artery, and thus
the Coxmaze III procedure evolved.9 However, a proportion
of patients still require pacemaker implantation after Cox
maze III, and even after PVI, suggesting that some candi-
dates for AF surgery have underlying SN dysfunction.
It is widely known that SN dysfunction is commonly asso-
ciated with AF and that patients with sick sinus syndrome
(SSS) frequently have AF.10,11 Therefore, we have
hypothesized that some patients who are surgical candidates
for AF have SN dysfunction and that PVI would be an
insufficient treatment for them. Here we report the long-term
results of cut-and-sew PVI for up to 6 years, focusing on SN
function.
PATIENTS AND METHODS
Patients
BetweenMay 2002 and September 2007, 88 consecutive patients under-
went cut-and-sew PVI at a single institution (Kokura Memorial Hospital).
Of these patients, 76 had persistent/permanent AF preoperatively. Intrao-
perative transesophageal echocardiography revealed no evidence of intra-
cardiac thrombus in 66 patients. These 66 were thought to be capable of
tolerating direct-current cardioversion and were enrolled in the presentdiovascular Surgery c Volume 141, Number 6 1455
TABLE 1. Preoperative patient demographics
Normal function
group (n ¼ 48)
Dysfunction
group (n ¼ 18)
P
value
Gender (male/female) 35/13 6/12 .003
Age (y) 63.6  1.7 68.7  2.4 .105
NYHA I 7 (15%) 1 (6%) .317
NYHA III/IV 12 (25%) 5 (28%) .818
History of embolism 8 (17%) 4 (22%) .602
Anticoagulant usage 39 (81%) 17 (94%) .293
Aspirin alone 10 (21%) 0 .031
Warfarin alone 3 (6%) 2 (11%) .539
Aspirinþwarfarin 26 (54%) 15 (83%) .045
Antiarrhythmia drug usage 36 (75%) 15 (83%) .472
Digitalis alone 13 9
Beta-blocker alnoe 6 1
Verapamil alone 5 1
Digitalisþbeta-blocker 3 2
Digitalisþbeta-blocker
þVerapamil
2 0
Digitalisþverapamil 1 1
Digitalisþpilsicainide 1 0
Digitalisþpimenol 1 0
Beta-blockerþVerapamil 2 0
Beta-blockerþverapamil
þPilsicainide
1 0
Verapamilþpilsicainide 1 0
Amiodarone alone 0 1
f Wave voltage in V1 (mV) 0.14  0.01 0.07  0.02 .003
CTR (%) 55.7  0.8 61.6  1.7 .005
LAD (mm) 50.5  1.1 53.4  1.7 .167
LVEF (%) 60.9  1.8 62.3  1.9 .649
Mitral valve disease 44 (92%) 18 (100%) .206
Degenerative MR 27 (56%) 12 (67%) .443
NYHA, New York Heart Association; CTR, cardiothoracic ratio; LAD, left atrial di-
mension; LVEF, left ventricular ejection fraction; MR, mitral regurgitation
Abbreviations and Acronyms
AF ¼ atrial fibrillation
ECG ¼ electrocardiogram
PVI ¼ pulmonary vein isolation
SN ¼ sinus node
SSS ¼ sick sinus syndrome
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Dstudy. Written consent was obtained from all patients after a full explana-
tion had been given before the operation. The study was approved by the
Institutional Review Board of Kokura Memorial Hospital in compliance
with the Declaration of Helsinki.
Immediately after the initiation of cardiopulmonary bypass, cardiover-
sion was performed before aortic crossclamping. If the heart was defibril-
lated, the overdrive suppression test was used and SN recovery time was
assessed. Patients were then divided into 2 groups: (1) a normal SN func-
tion group (n ¼ 48), which was defined as SN recovery time within 1 sec-
ond, and (2) an SN dysfunction group (n ¼ 18), which was defined as SN
recovery time of more than 1 second (n¼ 10) or not defibrillated (n¼ 8).12
Preoperative demographics are summarized in Table 1. Patients with SN
dysfunction had a significantly lower f wave voltage in V1 of the electrocar-
diogram (ECG) and a larger cardiothoracic ratio on chest x-ray films than
patients with normal SN function. Age, left atrial dimension, and left ven-
tricular ejection fraction did not differ between the groups.
Surgical Technique
After the examination of SN function, the aorta was clamped, and warm
blood cardioplegic solution was infused for myocardial protection. A right-
sided vertical incision in the left atrium was made and extended to encircle
all the pulmonary veins (as a box lesion), leaving 1.5 to 2 cm near the left
pulmonary vein to prevent separating the left atrium completely. Cryoabla-
tion was applied to this remnant for 180 seconds. The left atriumwas closed
with continuous sutures of 4–0 polypropylene. Operative procedures are
shown in Table 2. Mitral valve surgery was performed in 94% (62/66) of
the patients. Aortic clamping time and cardiopulmonary bypass time did
not differ significantly between the groups, irrespective of the concomitant
procedures (Table 2).
Postoperative Management and Follow-up
Both aspirin and warfarin were administrated to patients with valve
prostheses (19 patients in the normal SN function group and 11 in the
SN dysfunction group) and to patients without valve prostheses but having
frequent paroxysmal AF or sustained AF postoperatively (1 in the normal
SN function group and 5 in the SN dysfunction group). Antiarrhythmic
agents were not used prophylactically. Postoperative AF was treated
mainly with pilsicainide hydrochloride and with cardioversion in cases
of drug-resistant AF during hospitalization.
All information was collected and categorized in accordance with the
latest guidelines published in 2007.13 Patients were followed up at our out-
patient clinic at 1, 3, and 6 months after discharge and then annually, and
ECGs were recorded every time. Sixty of 61 survivors were followed up
at our outpatient clinic, and the remaining 1 patient, who had been hospi-
talized for treatment of dementia, was contacted directly by the physician.
The rate of complete follow-up was 100%. The cumulative follow-up time
was 162.3 patient-years, with a mean observation time of 29.5 months and
a range of 0.2 to 72 months.
Statistical Analysis
All values were expressed as mean  standard deviation. Continuous
variables were compared using the nonparametric Mann–Whitney U test.1456 The Journal of Thoracic and Cardiovascular SurProportions were compared using Fisher’s exact test. The event-free
survival curves were constructed using the Kaplan–Meier method, and dif-
ferences between the groups were investigated by log–rank test.RESULTS
Early Results
Operative mortality was 1.5% (n¼ 1), and hospital mor-
tality was 3% (n¼ 2). One patient with poor left ventricular
function and chronic renal dysfunction, who had undergone
both aortic and mitral valve replacement concomitantly,
died of multiple organ failure with systemic inflammatory
response syndrome on the sixth postoperative day. Another
patient, who had undergone aortic valve replacement using
a stentless valve prosthesis, died of mediastinitis on the 48th
postoperative day. Both were in the normal SN function
group. Nonfatal cerebral infarction occurred in another 2
patients in the normal SN function group during hospitali-
zation; one patient had Paf, and the other had no AF postop-
eratively. One patient in the SN dysfunction group
underwent pacemaker implantation for SSS beforegery c June 2011
TABLE 2. Operative procedure
Normal function
group (n ¼ 48)
Dysfunction group
(n ¼ 18)
P
value
Mitral valve procedure 44 18 .206
Repair 31 11
Replacement 13 7
Aortic valve/root
replacement
10 4 .902
Isolated 4 0
Concomitant 6 4
Coronary artery bypass 5 3 .537
Tricuspid annuloplasty 4 1
ASD closure 1 1
LV volume reduction 1 0
LAA resection 1 0
Aortic clamp time (min) 92.8  4.6 83.6  8.3 .308
CPB time (min) 118.5  4.9 110.1  10.0 .406
ASD, Atrial septal defect; LV, left ventricular; LAA, left atrial appendage; CPB, car-
diopulmonary bypass.
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Ddischarge. All of these early events were included the late
event analysis.
PostoperativeAFwas detected in 19 (41%) of the patients
in the normal SN function group and in 17 (94%) of those in
the SN dysfunction group during hospitalization, and this
difference was significant (P<.0001). Among them, cardi-
oversion was used for drug-resistant AF in 12 patients of the
normal SNF group and 6 patients of the SN dysfunction
group, respectively. At the time of discharge, 42 (91%) pa-
tients in the normal SN function group and 6 (33%) in the
SN dysfunction group were in sinus rhythm, and this differ-
ence was also significant (P<.0001). With regard to use of
antiarrhythmic agents, there was no significant intergroup
difference; 24 patients in the normal SN function group
and 10 in the SN dysfunction group (P ¼ .87).Late Results
There were 3 late deaths (1.8 %/patient-year). Two pa-
tients in the normal SN function group died of noncardiac
causes: liver dysfunction owing to cirrhosis and malig-
nancy, respectively. One patient in the SN dysfunction
group, who had been administered warfarin for longstand-
ing AF, died of cerebral hemorrhage.FIGURE 1. A, Actuarial freedom from death owing to all causes. B, Actuarial
sinus node function.
The Journal of Thoracic and CarFive nonfatal cardiac events occurred in the normal SN
function group: catheter ablation for atrial tachycardia or
paroxysmal AF in 2, redo mitral valve surgery in 2 (re-
repair and replacement, respectively), and percutaneous
coronary intervention in 1. The patient who underwent cath-
eter ablation for paroxysmal AF underwent pacemaker im-
plantation later.
In the SN dysfunction group, 3 cardiac events were
observed: implantation of a pacemaker for SSS in 2 and
of an implantable cardioverter defibrillator for ventricular
tachycardia in 1.
Actuarial freedom from death owing to all causes at 4
years was 85.1%  8.7% in the normal SN function group
and 94.1%  5.7% in the SN dysfunction group (Figure 1,
A). Actuarial freedom from cardiac death at 3 years was
100% in the normal SN function group and 94.1% 
5.7% in the SN dysfunction group (Figure 1, B). Late
thromboembolic events were not observed in either group.
During the follow-up period, AF was detected in 6 (13%)
patients in the normal SN function group and 11 (61%) in
the SN dysfunction group, and this difference was signifi-
cant (P< .0001). Actuarial freedom from cardiac events
at 4 years was 83.3%  6.7% in the normal SN function
group and 77.4%  10.0% in the SN dysfunction group.
There was no significant difference between the groups
(Figure 2, A).
Actuarial freedom from AF at 4 years in the normal SN
function group (82.3%  5.7%) was significantly better
than that in the SN dysfunction group (25.4%  12.9%)
(P< .001; Figure 2, B). At the time of the latest follow-
up, the ECG showed sinus rhythm in 88% of patients in
the normal SN function group, and this was also signifi-
cantly better than for patients in the SN dysfunction group
(41%; P<.001). Percentages of patients with sinus rhythm
confirmed by ECG during each follow-up period are shown
in Figure 3. About 90% of patients in the normal SN func-
tion group maintained sinus rhythm, compared with about
40% of patients in the SN dysfunction group.
Anticoagulation therapy was used in 31 of the patients in
the normal SN function group and in 16 of the patients in the
SN dysfunction group (P ¼ .17). Among them, warfarin
was used more frequently in the SN dysfunction groupfreedom from cardiac deaths. SND, Sinus node dysfunction; NSNF, normal
diovascular Surgery c Volume 141, Number 6 1457
FIGURE2. A,Actuarial freedom from cardiac events. B, Actuarial freedom from atrial fibrillation. SND, Sinus node dysfunction;NSNF, normal sinus node
function.
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(n ¼ 20, 42%; P ¼ .003).DISCUSSION
Major Findings
In the present study, we compared the results of cut-and-
sew PVI for persistent/permanent AF associated with heart
valve disease for up to 6 years between patients with normal
and abnormal SN function. The key findings were as fol-
lows: (1) Preoperatively, patients with SN dysfunction had
a significantly lower f wave voltage in V1 of the ECG and
a larger cardiothoracic ratio on chest x-ray films than pa-
tients with normal SN function; (2) at the time of discharge,
sinus rhythm was maintained in 42 (91%) of the patients
with normal SN function, compared with 6 (33%) of the pa-
tients with SN dysfunction (P<.0001); (3) there were no
significant differences between the groups in terms of free-
dom from death and cardiac events; (4) no late thromboem-
bolic events were observed in either of the groups; (5) the
rate of freedom from AF at 3 years in patients with normal
SN function (91%) was significantly higher than that in pa-
tients with SN dysfunction.Effect of PVI on Persistent/Permanent AF
The results of PVI seem to be comparable with those of
the Cox maze procedure in patients with paroxysmal AF.5
However, it is still not clearwhether PVI is an adequate treat-
ment for patients with persistent/permanent AF. The lack ofFIGURE 3. Percentage of sinus rhythm confirmed by electrocardiogram
during each follow-up period. POD, Postoperative day.
1458 The Journal of Thoracic and Cardiovascular Surlong-term results for PVI, especially using the most reliable
cut-and-sew technique, may be a major reason.
Kalil and colleagues1 have reported satisfactory early re-
sults of cut-and-sew PVI in 15 patients with chronic AF and
associated mitral valve disease, of whom 87.5% had
achieved sinus rhythm by 1 year after the operation. Sueda
and associates2 reported the results of PVI with the aid of
cryoablation or radiofrequency ablation for up to 4 years
in 49 patients with chronic persistent AF and heart disease,
including 41 patients with valvular disease. Of these pa-
tients, 71.4% and 70.2% were in sinus rhythm at discharge
and at the last follow-up, respectively. In a comparative
follow-up study of full maze, limited maze, and PVI with
the aid of radiofrequency ablation, Melby and associates3
reported that 59% of patients who received PVI were
free of AF at the time of follow-up. Another study by Gil-
linov and colleagues4 showed that 66% of patients were
free of AF 18 months after radiofrequency ablation and
clearly demonstrated that permanent AF was a risk factor
for AF recurrence. In the present study, both the overall
early and late cure rates were 75%. The use of energy sour-
ces other than the traditional cut-and-sew technique to cre-
ate atrial lesions may be one reason for the variety of
results, like the modifications of the maze procedure.5,6 It
seems that the cure rate after PVI has not yet reached
the level achieved after Cox maze III. In our series,
however, both the early and late cure rates in patients
with normal SN function were almost 90%, being
comparable with the Cox maze procedure. If limited to
patients with normal SN function, PVI appears to be
satisfactorily effective for persistent/permanent AF. In
patients without a corroboration of normal SN function,
however, another procedure such as Cox maze III may be
better than PVI.
SN Function and Persistent/Permanent AF
It is widely known that SN dysfunction is commonly as-
sociated with AF and that patients with SSS frequently have
AF.10,11 SN dysfunction has been attributed to fibrosis in the
SN and atria, with slowed conduction throughout the atrial
myocardium. In the presence of AF, further remodeling of
the SN and the atrial myocardium can occur.10,14 It isgery c June 2011
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Dthought that such histopathologic changes may be more
severe in patients with a longer history of AF. In fact,
a long AF duration is a significant risk factor for failure
of surgical PVI and the Cox maze procedure in patients
with persistent/permanent AF.4,15
In our series, patients with SN dysfunction had a signifi-
cantly lower f wave voltage in V1 of the ECG and a larger
cardiothoracic ratio on chest x-ray films than patients with
normal SN function preoperatively. These findings suggest
that patients with SN dysfunction may have a longer history
of AF than patients with normal SN function. However,
among patients with normal SN function, 1 patient who
had the largest cardiothoracic ratio (69%) in this series
and a left atrial dimension of 67 mm on echocardiography
preoperatively, maintained sinus rhythm throughout the
follow-up period. It is still unclear which preoperative
parameter is associated with SN dysfunction.
So far, there has been little information about the corre-
lation between SN dysfunction and outcome after PVI. In
the present study, we demonstrated that SN function can
be safely assessed intraoperatively and that 27% (18/66)
of the surgical candidates for persistent/permanent AF
had pre-existing SN dysfunction. In such patients, both
the early and late cure rates were significantly poorer than
in patients with normal SN function. Thus the effect of
PVI may be limited.
On the other hand, Hocini and coworkers16 have reported
an improvement of SN recovery time after catheter-based
PVI in patients with SSS. Khaykin and colleagues17 re-
ported a 1-year follow-up after catheter-based PVI in pa-
tients with SSS, in which the occurrence of syncopal/
presyncopal events or documented sinus pause was signifi-
cantly reduced after successful PVI in patients without per-
manent pacemakers (n ¼ 12), and the percentage of atrial
pacing was significantly reduced in patients with pace-
makers (n ¼ 19). These findings suggest that histopatho-
logic change in the SN and atria can be reversibly
remodeled and that PVI can lead to improvement of SN
function, although the mechanism responsible for the clin-
ical improvement is still unknown. Thus PVI still seems to
be an appropriate choice of therapy for some patients with
AF who have SN dysfunction.
Assessment of SN Function
In our present series, intraoperative assessment of SN
function was indicated for 66 of 76 patients with persis-
tent/permanent AF. It is essential to confirm whether throm-
bus is present in the heart before cardioversion. The use of
transesophageal echocardiography and complete unloading
of the heart under extracorporeal circulation can minimize
the risk of thromboembolism and make the patient more
comfortable. From these viewpoints, intraoperative assess-
ment is more advantageous than when the patient is awake.
The 2 early nonfatal cerebral infarctions in our series did notThe Journal of Thoracic and Carseem to be associated with cardioversion because both oc-
curred outside the perioperative period.
Among the 44 survivors in the normal SN function group,
in whom the heart was defibrillated by cardioversion, 88%
maintained their sinus rhythm during the follow-up period.
In contrast, only 1 (14%) patient maintained sinus rhythm
among the 7 survivors in the SN dysfunction group, in
whom the heart was not defibrillated. This suggests that re-
sponse to cardioversion may be a simpler parameter for pre-
diction of SN function. However, SN function is difficult to
examine if a patient has a thrombus. The ideal method is one
that can be done safely and quickly, and which is feasible
for all patients.
Limitations
This study had certain limitations. First, it was a retro-
spective analysis, and the number of patients was relatively
small. We acknowledge that large multicenter randomized
prospective trials would provide the most reliable data for
effective lesion sets in patients with persistent/permanent
AF and SN dysfunction. However, it has been difficult to
identify patients with SN dysfunction among those with
persistent/permanent AF who are candidates for surgery.
The merit of the present series was that it was a single-
center study of operations performed by a single surgeon,
with the longest follow-up period yet reported. Second,
the present study lacks Holter ECG recordings. Finally,
SN function was not completely examined in patients
who could not be cardioverted intraoperatively. It should
be noted that the SN dysfunction group in this series
indicates patients without a corroboration of normal SN
function.
CONCLUSIONS
Our follow-up study covering a period of up to 6 years af-
ter cut-and-sew PVI has demonstrated that the early and late
cure rates of AF in patients with normal SN function were
satisfactory and comparable with those after the Cox
maze III procedure. In contrast, the results in patients
with SN dysfunction were significantly poorer. Assessment
of SN function may help to improve the success rate after
PVI in patients with persistent/permanent AF associated
with heart valve disease.
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